StockData
Cocrystal Pharma, Inc. logo

Cocrystal Pharma, Inc. (COCP) stock

COCPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$0.98−0.03 (-3.28%)

Close on Nov 18, 2026Market cap $18.82MP/E –Yield –

Cocrystal Pharma revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Cocrystal Pharma's revenue for the twelve months ending Dec 31, 2020 was $2.01M, down 69.3% year over year. For fiscal 2020 it was $2.01M, down 69.3% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2020Dec 31, 2020$2.01M-69.3%
FY2019Dec 31, 2019$6.56M-48.4%
FY2011Dec 31, 2011$12.71M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$105.00K-81.0%
Q1 FY2026Mar 31, 2026$225.00K-51.2%
Q4 FY2020Dec 31, 2020$510.00K+26.9%
Q3 FY2020Sep 30, 2020$489.00K-0.6%
Q2 FY2020Jun 30, 2020$554.00K-6.4%
Q1 FY2020Mar 31, 2020$461.00K-90.9%
Q4 FY2019Dec 31, 2019$402.00K–
Q3 FY2019Sep 30, 2019$492.00K–
Q2 FY2019Jun 30, 2019$592.00K–
Q1 FY2019Mar 31, 2019$5.08M–

More Cocrystal Pharma figures

See a number that looks wrong?